ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the agency’s proposed rulemaking revisions to the Medicare Prescription Drug Benefit Program (Part D) for 2019. ASCO applauds CMS for its efforts to advance the Part D program’s goal of promoting access to prescription drug therapies at an affordable cost to beneficiaries and urges the implementation of high-quality clinical pathways to promote access to the right drug, for the right patient, at the right time.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
On January 22, the U.S. Senate and U.S. House of Representatives voted to pass a short-term Continuing Resolution (CR) to keep the federal government funded through February 8, 2018. The CR, which President Trump signed into law, ends a three-day federal government shutdown and keeps funding levels flat for federal agencies, including the National Institutes of Health (NIH) and the National Cancer Institute (NCI).
ASCO will host Precision Medicine: Expanding Opportunities, a robust panel discussionto focus on the United States’ challenges in precision medicine – from the overwhelming complexity of tumors, to the costs of treatment, to regulatory barriers that impede widespread use – and the solutions needed to overcome them.
ASCO published its first ASCO in Action Podcast, hosted by ASCO CEO Dr. Clifford Hudis and featuring Dr. Karen Winkfield who discusses ethnic and racial diversity in the oncology workforce, and ASCO’s strategic plan for addressing this issue.
Clinica AMO has become the second practice in Brazil to receive Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program, LLC, and the sixth practice internationally to receive this accreditation.
In January 2018, ASCO will launch the ASCO in Action Podcast, a new podcast series that will provide analysis and commentary on cancer policy and practice issues. ASCO Chief Executive Officer Dr. Clifford Hudis is the host of the new podcast series and will interview thought leaders and experts on current policy and practice issues in oncology.
ASCO and the American Society for Radiation Oncology have launched their new, joint platform for quality reporting, making it easier for oncologists to comply with federal government reporting requirements in 2018.
The U.S. Department of Health and Human Services (HHS) announced that implementation of the updated Common Rule will be delayed until July 19, 2018 instead of taking effect on January 19, 2018.
ASCO submitted a comment letter to the Centers for Medicare & Medicaid Services (CMS) on coverage of next generation sequencing (NGS) for Medicare beneficiaries with advanced cancer.
CancerLinQ LLC and the Association for Molecular Pathology (AMP), a global, molecular diagnostics professional society, have entered into a collaboration. AMP leadership and members will be applying the breadth of their knowledge to CancerLinQ®, the American Society of Clinical Oncology’s (ASCO) health information technology platform designed to leverage the power of big data to help conquer cancer.
The Oncology Center of Excellence of the Food and Drug Administration is informing health care providers about new safety information for Varubi® (rolapitant) injectable emulsion, a substance P/neurokinin (NK-1) receptor antagonist indicated for the prevention of delayed nausea and vomiting associated with cancer chemotherapy in adults.
On January 12, 2018, the Food and Drug Administration granted regular approval to olaparib tablets (Lynparza® , AstraZeneca Pharmaceuticals LP), a poly (ADP-ribose) polymerase (PARP) inhibitor, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting.
On January 12, 2018, the Food and Drug Administration granted approval to afatinib (Gilotrif®, Boehringer Ingelheim Pharmaceutical, Inc.) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
CancerLinQ LLC and the National Society of Genetic Counselors, the professional society for genetic counselors, announced today that they have entered into a strategic alliance.
ASCO sent a letter to CMS to comment on the proposed notice, “Patient Protection and Affordable Care Act; Health and Human Services (HHS) Notice of Benefit and Payment Parameters for 2019” and expressed concerns that it would fundamentally alter many of the consumer and patient protections in individual and small group markets and lead to the establishment of qualified health plans that would fail to address the comprehensive medical needs of patients with cancer.